With the FDA-approved r-EEG database, we can determine if psychiatric medications are suitable for you.

 

An objective, physiological database that helps us choose a medication when developing a treatment plan for patients with psychiatric illnesses who do not respond to treatment can be quite valuable.

The FDA-approved r-EEG database was developed in the United States as a result of 17 years of scientific and objective research.

The analysis of artifact-free EEGs recorded with the FDA-approved QEEG system against the r-EEG database using FDA-approved software analysis is crucial in determining which medication is sensitive and which medication will be effective.

The study includes 2500 patients, 12,000 treatments, and more than 6 months of follow-up. The results of 8000 treatment episodes are parallel to the sensitivity of drug and drug groups to drug response according to the deviant QEEG database.

When planning medication for very difficult patients, the goal should be to select parallel and specific medications according to the patient and their illness.

 

This database can be used for r-EEG testing in two different ways.

Type 1: The patient should be medication-free, and the aim is to determine which medications are sensitive, resistant, or moderately sensitive for that patient, including antiepileptic drugs, benzodiazepines, antidepressants, stimulants, and beta-blockers. It is used to determine whether a total of 30 different medications from these groups are sensitive for that patient.

Type 2: This is an EEG test performed while the patient is on medication, to observe the effect of the selected medication(s) from among these 30 medications. It predicts which medication will be beneficial for that patient with an 80% accuracy rate.

IBH insurance companies in America cover r-EEG costs.

In one study, 50 out of 100 patients had depression and 50 had attention deficit disorder. They selected the drug that would respond to treatment with an 80% accuracy rate.

 

Should the drug be chosen based on the patient's symptoms or on the electrical irregularities in their brain? A database with an 80% accuracy rate provided the answer to this question (Stephen C. Suffin & W. Hamlin Emory, 1995).

 

Another study, conducted by Suffin S. C. (1999) et al., investigated which drug had a therapeutic effect using r-EEG in patients with major depression who did not respond to medication.

 

This study, conducted with depression patients who had not responded to treatment for an average of 16 years and had been hospitalized at least once, aimed to see if r-EEG could help select the appropriate drug even in the most difficult cases.

 

This is a double-blind study conducted at UCLA. Improvement was observed in 85% of these patients. Of 58 patients with dual diagnoses (both drug addiction and psychiatric illness), 56 benefited.

In another study conducted at the University of California using r-EEG, Schiller et al. (2008) found that in 65 patients with Dual Diagnosis (non-psychotic patients diagnosed with Axis 1, who also had alcohol and drug dependence), the success of treatment was increased by drug selection using r-EEG.

Greenblatt et al. (2008) also reported that they were more successful in treating 16 patients with treatment-resistant Eating Disorders and Depression using drugs selected with r-EEG reference, and they followed the patients for a maximum of 2 years.

A group of researchers from Stanford University, the University of California, and Harvard Medical School found that the success rate of treatment increased in a randomized blinded study of 18 patients with drug-resistant Depression using r-EEG reference (DeBattista C., 2008).

Another study conducted by the University of California and the CNS Response group addressed the FDA's warning that SSRI antidepressants increase the risk of suicide in children and adolescents. The aim was to reduce the unnecessary use of SSRI antidepressants and to protect children from the suicidal side effects of the medication if it is not effective. They used r-EEG to determine which group of drugs would work in a child or adolescent and tested its effectiveness (Hoffman, D. A., 2008).

They found that 48 out of 65 child patients would not respond to SSRI antidepressants and were being given these medications unnecessarily. Therefore, they concluded that it is not worth taking SSRI antidepressants, which have little or no effect, due to the suicidal side effect.